Innocenti F - Search Results

1

Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.

Roncato R, Cecchin E, Montico M, De Mattia E, Giodini L, Buonadonna A, Solfrini V, Innocenti F, Toffoli G. Roncato R, et al. Among authors: innocenti f. Clin Pharmacol Ther. 2017 Jul;102(1):123-130. doi: 10.1002/cpt.615. Epub 2017 Mar 20. Clin Pharmacol Ther. 2017. PMID: 28074472

2

Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients.

Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, Mini E, Boiocchi M. Toffoli G, et al. Among authors: innocenti f. Int J Cancer. 2003 Jan 20;103(3):294-9. doi: 10.1002/ijc.10847. Int J Cancer. 2003. PMID: 12471611

3

Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.

Innocenti F, Ratain MJ. Innocenti F, et al. Oncology (Williston Park). 2003 May;17(5 Suppl 5):52-5. Oncology (Williston Park). 2003. PMID: 12800608 Review.

4

"Irinogenetics" and UGT1A: from genotypes to haplotypes.

Innocenti F, Ratain MJ. Innocenti F, et al. Clin Pharmacol Ther. 2004 Jun;75(6):495-500. doi: 10.1016/j.clpt.2004.01.011. Clin Pharmacol Ther. 2004. PMID: 15179404 Review. No abstract available.

5

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.

Innocenti F, Undevia SD, Ramírez J, Mani S, Schilsky RL, Vogelzang NJ, Prado M, Ratain MJ. Innocenti F, et al. Clin Pharmacol Ther. 2004 Nov;76(5):490-502. doi: 10.1016/j.clpt.2004.07.016. Clin Pharmacol Ther. 2004. PMID: 15536463 Clinical Trial.

6

MTHFR and ALL risk: a challenge.

Toffoli G, Innocenti F. Toffoli G, et al. Among authors: innocenti f. Leuk Lymphoma. 2006 Jul;47(7):1203-4. doi: 10.1080/10428190600725461. Leuk Lymphoma. 2006. PMID: 16923547 No abstract available.

7

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.

Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JV. Ramchandani RP, et al. Among authors: innocenti f. J Clin Pharmacol. 2007 Jan;47(1):78-86. doi: 10.1177/0091270006295060. J Clin Pharmacol. 2007. PMID: 17192505

8

Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.

Corona G, Vaccher E, Sandron S, Sartor I, Tirelli U, Innocenti F, Toffoli G. Corona G, et al. Among authors: innocenti f. Clin Pharmacol Ther. 2008 Apr;83(4):601-6. doi: 10.1038/sj.clpt.6100330. Epub 2007 Aug 22. Clin Pharmacol Ther. 2008. PMID: 17713471

9

Pharmacogenetic pathway analysis of irinotecan.

Rosner GL, Panetta JC, Innocenti F, Ratain MJ. Rosner GL, et al. Among authors: innocenti f. Clin Pharmacol Ther. 2008 Sep;84(3):393-402. doi: 10.1038/clpt.2008.63. Epub 2008 Apr 16. Clin Pharmacol Ther. 2008. PMID: 18418374 Free PMC article.

10

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G. Cecchin E, et al. Among authors: innocenti f. J Clin Oncol. 2009 May 20;27(15):2457-65. doi: 10.1200/JCO.2008.19.0314. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364970

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

435 results

Search Page

Filters